You just read:

IMBRUVICA® (ibrutinib) Data Provide Insights Into Its Potential Treatment Benefits for Previously-Treated Chronic Graft-Versus-Host Disease -- A Serious, Possibly Life-Threatening Condition

News provided by

AbbVie

Dec 11, 2017, 09:00 EST